Physician profile
Joseph Zahn
NPI 1386058048
$1,924.08
in general payments reported to CMS, 2019-2025
15 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $264 · 2021: $686 · 2022: $742 · 2023: $76.69 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $232.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $451.41 | 2020-2023 | Rinvoq |
| Incyte Corporation | $340.28 | 2021-2025 | Opzelura, Opzelura |
| Janssen Biotech, INC. | $178.67 | 2020-2022 | |
| Leo Pharma INC. | $170.15 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $164.90 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $152.92 | 2021-2022 | |
| Amgen INC. | $120.04 | 2021-2023 | Enbrel, Otezla |
| Pfizer INC. | $83.58 | 2021-2022 | |
| Genzyme Corporation | $79.47 | 2020-2022 | |
| Sun Pharmaceutical Industries INC. | $65.14 | 2020-2021 | |
| Almirall LLC | $38.22 | 2021-2022 | |
| Dermira, INC. | $27.15 | 2020 | |
| Ucb, INC. | $20.82 | 2021 | |
| Biofrontera INC. | $19.29 | 2022 | |
| Regeneron Pharmaceuticals, INC. | $12.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Zahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.